Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
about
Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea AttentionNovel concepts in radiation-induced cardiovascular disease.Differential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.Rac1 modulates acute and subacute genotoxin-induced hepatic stress responses, fibrosis and liver agingAddressing the Symptoms or Fixing the Problem? Developing Countermeasures against Normal Tissue Radiation Injury.Targeting tumor cell metabolism with statins.Radioprotectors - the evergreen topic.Radioprotective Agents: Strategies and Translational Advances.mESC-based in vitro differentiation models to study vascular response and functionality following genotoxic insults.Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.Novel Indications for Commonly Used Medications as Radiation Protectants in Spaceflight.Pulmonary toxicity generated from radiotherapeutic treatment of thoracic malignancies.Simvastatin ameliorates ionizing radiation-induced apoptosis in the thymus by activating the AKT/sirtuin 1 pathway in mice.Rac1 promotes diethylnitrosamine (DEN)-induced formation of liver tumors.Strategies to optimize radiotherapy based on biological responses of tumor and normal tissue.Simvastatin improves hematopoietic stem cell engraftment by preventing irradiation-induced marrow adipogenesis and radio-protecting the niche cells.HMG-CoA reductase inhibition delays DNA repair and promotes senescence after tumor irradiation.Upregulation of Plasminogen Activator Inhibitor-1 in Irradiated Recipient Arteries and Veins from Free Tissue Transfer Reconstruction in Cancer Patients
P2860
Q28069232-DC4F3370-F16B-48CF-BC61-ED9FD8A67FB8Q28071302-BEC988B4-729A-4DF4-AD7C-C44B6202F6B2Q34428844-28E57172-C1D2-4DFD-858E-06D7093CA320Q36733195-55F08506-027F-4A93-8EFE-5F7B74C4F8DDQ37189966-0E687F0C-9F1B-43C6-89F3-24E12A0C08EDQ37981833-2928EDD8-DC2F-4283-8F2F-B5D72E44973FQ38153018-A9161CF9-3308-4322-849E-DD4DAC2B7317Q38710560-79F84E48-93C6-464D-BE5D-353A33BBCE6BQ38927821-FB1EC552-1999-45FF-B5E4-C8353CAA110FQ39012650-3869FF42-5139-48BC-A02C-20C613638BA1Q39391997-FD76A567-C528-403C-A5CB-DF712A9133DFQ39426003-7F10887B-129E-40F7-854D-50CB19CADEAEQ41296905-D576CF3C-90D6-49B9-9765-7492D6EEC860Q41629566-77928925-1F05-4822-A7AA-C5085118214AQ41984684-811341B8-D6CB-4177-872D-1C7ACB45E205Q42399851-C5E31121-0482-4A93-9762-D2DED97E631AQ47655012-6E0BB096-40D1-45AC-A04C-054C3E3AB74AQ58584606-B143F140-0368-46DF-95AD-ED90A5711AC2
P2860
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
@en
Potential use of HMG-CoA reductase inhibitors
@nl
type
label
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
@en
Potential use of HMG-CoA reductase inhibitors
@nl
prefLabel
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
@en
Potential use of HMG-CoA reductase inhibitors
@nl
P2860
P356
P1476
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents
@en
P2093
Gerhard Fritz
Johannes Huelsenbeck
P2860
P356
10.1093/BMB/LDQ044
P577
2011-01-20T00:00:00Z